Stimera, Tahoe Vista, California, the crop science company formerly known as BioAge, has announced the appointment of Lon E. Kreger has been appointed as CEO.
The leadership transition marks an important step in the company’s evolution as it moves from product validation and early market traction toward broader commercial scale.
Stimera is developing patent-pending molecular foliar fertilizers designed to make nutrients behave like biostimulants. Its flagship product, Nitro-Gro, is engineered to alter the molecular structure of nutrient inputs, allowing them to enter leaves rapidly, activate electrochemical nutrient transport, and accelerate plant metabolism. In current company materials, Stimera positions the platform around independently validated, customer-proven results, targeting roughly 30% higher yield, crop cycles shortened by up to two weeks, and up to 5x same-season return on investment.
Kreger’s appointment comes as Stimera expands from regional product development to global commercialization. Designed to serve the grower, the company’s multi-channel strategy leverages trusted agricultural retailers, distributors, and manufacturing partners to bring its solutions directly to market.
Stimera’s technology was developed by Reuben R. Rampersad, founder and president. Rampersad brings deep expertise in formulation science and agricultural strategy, focusing on solutions that accelerate growth, improve nutrient efficiency, and unlock commercial-scale farming across international markets.
“Using scientific rigor, Reuben created a new category of crop inputs—molecular fertilizers—to develop the next generation of plant nutrition,” Kreger said. “Reuben is a visionary scientist who realized an impactful change was needed. My role is to put this technology into the hands of the grower—who it was designed to benefit.”
Rampersad will continue as founder and president, leading product development, formulation strategy, and pipeline expansion. Current company materials indicate Stimera has roughly 20 products in development, with about 30% at or near commercialization.
For more information, visit stimera.ag.
